{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:22:20Z","timestamp":1787818940824,"version":"build-2784847793"},"reference-count":165,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Uveitis in Beh\u00e7et\u2019s disease (BD) is frequent (40% of cases) and is a major cause of morbidity. The age of onset of uveitis is between 20 and 30 years. Ocular involvement includes anterior, posterior, or panuveitis. Uveitis may be the first sign of the disease in 20% of cases or it may appear 2 or 3 years after the first symptoms. Panuveitis is the most common presentation and is more commonly found in men. Bilateralization usually occurs on average 2 years after the first symptoms. The estimated risk of blindness at 5 years is 10\u201315%. BD uveitis has several ophthalmological features that distinguish it from other uveitis. The main goals in the management of patients are the rapid resolution of intraocular inflammation, the prevention of recurrent attacks, the achievement of complete remission, and the preservation of vision. Biologic therapies have changed the management of intraocular inflammation. The aim of this review is to provide an update to a previous article by our team on pathogenesis, diagnostic approaches, and the therapeutic strategy of BD uveitis.<\/jats:p>","DOI":"10.3390\/jcm12113648","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T02:00:55Z","timestamp":1684980055000},"page":"3648","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Beh\u00e7et\u2019s Disease Uveitis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-0459","authenticated-orcid":false,"given":"Morgane","family":"Joubert","sequence":"first","affiliation":[{"name":"AP-HP. Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques Rares, Centre de R\u00e9f\u00e9rence des Maladies Auto-Inflammatoires et de l\u2019Amylose Inflammatoire, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Desbois","sequence":"additional","affiliation":[{"name":"AP-HP. Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques Rares, Centre de R\u00e9f\u00e9rence des Maladies Auto-Inflammatoires et de l\u2019Amylose Inflammatoire, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Domont","sequence":"additional","affiliation":[{"name":"AP-HP. Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques Rares, Centre de R\u00e9f\u00e9rence des Maladies Auto-Inflammatoires et de l\u2019Amylose Inflammatoire, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Ghembaza","sequence":"additional","affiliation":[{"name":"AP-HP. Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques Rares, Centre de R\u00e9f\u00e9rence des Maladies Auto-Inflammatoires et de l\u2019Amylose Inflammatoire, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Le Joncour","sequence":"additional","affiliation":[{"name":"AP-HP. Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques Rares, Centre de R\u00e9f\u00e9rence des Maladies Auto-Inflammatoires et de l\u2019Amylose Inflammatoire, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Mirouse","sequence":"additional","affiliation":[{"name":"AP-HP. Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques Rares, Centre de R\u00e9f\u00e9rence des Maladies Auto-Inflammatoires et de l\u2019Amylose Inflammatoire, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4554-1922","authenticated-orcid":false,"given":"Georgina","family":"Maalouf","sequence":"additional","affiliation":[{"name":"AP-HP. Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques Rares, Centre de R\u00e9f\u00e9rence des Maladies Auto-Inflammatoires et de l\u2019Amylose Inflammatoire, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Leclercq","sequence":"additional","affiliation":[{"name":"CHU Rouen, Internal Medicine Department, F-76000 Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Touhami","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, Sorbonne Universit\u00e9s, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6727-4992","authenticated-orcid":false,"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[{"name":"AP-HP. Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques Rares, Centre de R\u00e9f\u00e9rence des Maladies Auto-Inflammatoires et de l\u2019Amylose Inflammatoire, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, Sorbonne Universit\u00e9s, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[{"name":"AP-HP. Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques Rares, Centre de R\u00e9f\u00e9rence des Maladies Auto-Inflammatoires et de l\u2019Amylose Inflammatoire, F-75013 Paris, France"},{"name":"Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale (INSERM), Unit\u00e9 M\u00e9dical de Recherche (UMR)S 59, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current concepts in the etiology and treatment of Beh\u00e7et disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Surv. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/S0248-8663(02)00665-3","article-title":"Interf\u00e9ron et maladie de Beh\u00e7et","volume":"23","author":"Wechsler","year":"2002","journal-title":"Rev. M\u00e9d. Interne"},{"key":"ref_3","first-page":"529","article-title":"Ocular manifestations of Beh\u00e7et\u2019s disease","volume":"150","author":"Cassoux","year":"1999","journal-title":"Ann. Med. Interne"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et\u2019s disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Leclercq, M., Desbois, A.-C., Domont, F., Maalouf, G., Touhami, S., Cacoub, P., Bodaghi, B., and Saadoun, D. (2020). Biotherapies in Uveitis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113599"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gueudry, J., Leclercq, M., Saadoun, D., and Bodaghi, B. (2021). Old and New Challenges in Uveitis Associated with Beh\u00e7et\u2019s Disease. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112318"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s13023-020-01620-4","article-title":"French recommendations for the management of Beh\u00e7et\u2019s disease","volume":"16","author":"Barete","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/1744666X.2016.1205486","article-title":"Behcet\u2019s disease: Epidemiology, clinical manifestations, and diagnosis","volume":"13","author":"Davatchi","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/art.24423","article-title":"Epidemiology and clinical characteristics of Beh\u00e7et\u2019s disease in the US: A population-based study","volume":"61","author":"Calamia","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/bmj.304.6836.1199","article-title":"Beh\u00e7et\u2019s disease","volume":"304","author":"Wechsler","year":"1992","journal-title":"Br. Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12969-016-0070-z","article-title":"Beh\u00e7et\u2019s disease in children, an overview","volume":"14","year":"2016","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/archopht.1970.00990040453009","article-title":"The rate of visual loss in Beh\u00e7et\u2019s disease","volume":"84","author":"Mamo","year":"1970","journal-title":"Arch. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: An analysis of 880 patients","volume":"138","author":"Onal","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09273948.2012.723112","article-title":"Epidemiology of Beh\u00e7et disease","volume":"20","author":"Khairallah","year":"2012","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3389\/fimmu.2019.01085","article-title":"Beh\u00e7et\u2019s Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils","volume":"10","author":"Emmi","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2559.2000.00859.x","article-title":"Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Beh\u00e7et disease","volume":"36","author":"Kobayashi","year":"2000","journal-title":"Histopathology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00403-009-1008-9","article-title":"The skin pathergy test: Innately useful?","volume":"302","author":"Varol","year":"2010","journal-title":"Arch. Dermatol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/rheumatology\/kes399","article-title":"Pro-inflammatory cytokine and caspase-1 responses to pattern recognition receptor activation of neutrophils and dendritic cells in Behcet\u2019s disease","volume":"52","author":"Tulunay","year":"2013","journal-title":"Rheumatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.3346\/jkms.2020.35.e213","article-title":"Neutrophil-mediated Thrombosis and NETosis in Beh\u00e7et\u2019s Disease: A Hypothesis","volume":"35","author":"Batu","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","article-title":"Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Beh\u00e7et Disease","volume":"133","author":"Becatti","year":"2016","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/08820139.2017.1288240","article-title":"Natural Killer Cell Subsets and Their Functional Activity in Beh\u00e7et\u2019s Disease","volume":"46","author":"Cosan","year":"2017","journal-title":"Immunol. Invest."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar3005","article-title":"Natural killer cells control a T-helper 1 response in patients with Beh\u00e7et\u2019s disease","volume":"12","author":"Yamaguchi","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_23","first-page":"2301","article-title":"Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Beh\u00e7et\u2019s disease","volume":"21","author":"Hamzaoui","year":"1994","journal-title":"J. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"705831","DOI":"10.1155\/2015\/705831","article-title":"Gamma Delta (\u03b3\u03b4) T Cells and Their Involvement in Beh\u00e7et\u2019s Disease","volume":"2015","author":"Hasan","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","article-title":"Beh\u00e7et\u2019s disease: New insights into pathophysiology, clinical features and treatment options","volume":"17","author":"Greco","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/art.11074","article-title":"Human \u03b1-enolase from endothelial cells as a target antigen of anti\u2013endothelial cell antibody in Beh\u00e7et\u2019s disease","volume":"48","author":"Lee","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.autrev.2009.10.005","article-title":"Etiopathogenesis of Behcet\u2019s disease","volume":"9","author":"Espinosa","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Errera, M.-H., Pratas, A., Fisson, S., Manicom, T., Boubaya, M., Sedira, N., H\u00e9ron, E., Merabet, L., Kobal, A., and Levy, V. (2022). Cytokines, chemokines and growth factors profile in human aqueous humor in idiopathic uveitis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0254972"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fimmu.2020.00358","article-title":"Cytokine Profiling in Aqueous Humor Samples from Patients with Non-Infectious Uveitis Associated with Systemic Inflammatory Diseases","volume":"11","author":"Bonacini","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1684\/ecn.2019.0421","article-title":"IL-17, IL-10, IL-6, and IFN-\u03b3 in Egyptian Beh\u00e7et\u2019s disease: Correlation with clinical manifestations","volume":"30","author":"Talaat","year":"2019","journal-title":"Eur. Cytokine Netw."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Beh\u00e7et Patients with Active Uveitis","volume":"49","author":"Chi","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100866","DOI":"10.1016\/j.preteyeres.2020.100866","article-title":"Activation of the interleukin-23\/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis","volume":"80","author":"Zhong","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ng.625","article-title":"Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R\/IL12RB2 regions associated with Beh\u00e7et\u2019s disease","volume":"42","author":"Remmers","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5606\/ArchRheumatol.2018.6704","article-title":"Association of MICA Alleles and Human Leukocyte Antigen B in Turkish Patients Diagnosed with Beh\u00e7et\u2019s Disease","volume":"33","author":"Eyerci","year":"2018","journal-title":"Arch. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107853","DOI":"10.1016\/j.exer.2019.107853","article-title":"Uveitis genetics","volume":"190","author":"Hou","year":"2020","journal-title":"Exp. Eye Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti\u2013Tumor Necrosis Factor \u03b1 versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network","volume":"129","author":"Leclercq","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/09273948.2012.713159","article-title":"Comparison of presenting features and three-year disease course in Turkish patients with Beh\u00e7et uveitis who presented in the early 1990s and the early 2000s","volume":"20","author":"Cingu","year":"2012","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.revmed.2018.02.022","article-title":"Ocular manifestations in Beh\u00e7et\u2019s disease","volume":"39","author":"Desbois","year":"2018","journal-title":"Rev. Med. Interne"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD), Davatchi, F., Assaad-Khalil, S., Calamia, K.T., Crook, J.E., Sadeghi-Abdollahi, B., Schirmer, M., Tzellos, T., Zouboulis, C.C., and Akhlagi, M. (2014). The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J. Eur. Acad. Dermatol. Venereol., 28, 338\u2013347.","DOI":"10.1111\/jdv.12107"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_41","first-page":"225","article-title":"The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Beh\u00e7et\u2019s disease in Japan: Ophthalmologic aspects","volume":"77","author":"Mishima","year":"1979","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_42","first-page":"175","article-title":"Relationship between age at onset and clinical characteristics of Beh\u00e7et\u2019s disease","volume":"27","author":"Ghembaza","year":"2018","journal-title":"Acta Dermatovenerol. Alp. Pannonica Adriat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/09273948.2013.795228","article-title":"Differential diagnosis of beh\u00e7et uveitis","volume":"21","author":"Gupta","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4274\/tjo.77632","article-title":"Vitreomacular Interface Disorders in Beh\u00e7et\u2019s Uveitis","volume":"47","year":"2017","journal-title":"Turk. J. Ophthalmol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ajo.2014.11.029","article-title":"Nonglaucomatous localized retinal nerve fiber layer defects in Beh\u00e7et uveitis","volume":"159","author":"Oray","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/IIO.0b013e318265d56a","article-title":"Imaging in the diagnosis and management of Beh\u00e7et disease","volume":"52","year":"2012","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/eye.2014.138","article-title":"Long-term efficacy of infliximab on background vascular leakage in patients with Beh\u00e7et\u2019s disease","volume":"28","author":"Keino","year":"2014","journal-title":"Eye"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40942-018-0117-z","article-title":"Comparison between optical coherence tomography angiography and fluorescein angiography findings in retinal vasculitis","volume":"4","author":"Torricelli","year":"2018","journal-title":"Int. J. Retina Vitr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/09273948.2016.1205100","article-title":"Review for Diagnostics of the Year: Multimodal Imaging in Beh\u00e7et Uveitis","volume":"25","author":"Ozdal","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8612","DOI":"10.1038\/s41598-019-45149-4","article-title":"Association between subfoveal choroidal thickness and leakage site on fluorescein angiography in Beh\u00e7et\u2019s uveitis","volume":"9","author":"Shirahama","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/IAE.0000000000001587","article-title":"Quantitative analysis of structural alterations in the choroid of patients with active beh\u00e7et uveitis","volume":"38","author":"Onal","year":"2018","journal-title":"Retina"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/09273948.2019.1612452","article-title":"Optical Coherence Tomography Angiography Findings in Active and Inactive Ocular Beh\u00e7et Disease","volume":"28","author":"Accorinti","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2180723","DOI":"10.1155\/2017\/2180723","article-title":"Assessment of Vascular Change Using Swept-Source Optical Coherence Tomography Angiography: A New Theory Explains Central Visual Loss in Behcet\u2019s Disease","volume":"2017","author":"Somkijrungroj","year":"2017","journal-title":"J. Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1080\/09273948.2020.1736310","article-title":"An Algorithm for the Diagnosis of Beh\u00e7et Disease Uveitis in Adults","volume":"29","author":"Onal","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_55","first-page":"319","article-title":"Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study","volume":"24","author":"Hamam","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1080\/09273948.2017.1335756","article-title":"Intravitreal Adalimumab for the Control of Breakthrough Intraocular Inflammation","volume":"26","author":"Kheir","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/09273948.2019.1685108","article-title":"Analysis of Parafoveal Microvascular Abnormalities in Behcet\u2019s Uveitis Using Projection-Resolved Optical Coherence Tomographic Angiography","volume":"29","author":"Pei","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/iovs.62.3.8","article-title":"Parafoveal Microvascular Alterations in Ocular and Non-Ocular Beh\u00e7et\u2019s Disease Evaluated with Optical Coherence Tomography Angiography","volume":"62","author":"Smid","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/IAE.0000000000002177","article-title":"Optical coherence tomography angiography findings in patients with nonocular beh\u00e7et disease","volume":"39","author":"Raafat","year":"2019","journal-title":"Retina"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s10792-018-1059-z","article-title":"Quantitative analysis of retinal microcirculation in optical coherence tomography angiography in cases with Beh\u00e7et\u2019s disease without ocular involvement","volume":"39","year":"2019","journal-title":"Int. Ophthalmol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1038\/s41433-020-01294-z","article-title":"Preclinical ocular features in patients with Beh\u00e7et\u2019s disease detected by optical coherence tomography angiography","volume":"35","author":"Karalezli","year":"2021","journal-title":"Eye"},{"key":"ref_62","unstructured":"(2022, November 01). Use of Laser Flare-Cell Photometry to Quantify Intraocular Inflammation in Patients with Beh\u00e7et Uveitis\u2014PubMed, Available online: https:\/\/pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr\/18504599\/."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/09273948.2013.866257","article-title":"Therapy of ocular Beh\u00e7et disease","volume":"22","author":"Zierhut","year":"2014","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14712598.2019.1595578","article-title":"Expert opinion on the use of biological therapy in non-infectious uveitis","volume":"19","author":"Touhami","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_65","first-page":"808","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","article-title":"Management of major organ involvement of Beh\u00e7et\u2019s syndrome: A systematic review for update of the EULAR recommendations","volume":"57","author":"Ozguler","year":"2018","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Beh\u00e7et\u2019s Disease","volume":"125","author":"Mesquida","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ajo.2022.02.002","article-title":"Lower Relapses Rate with Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients","volume":"238","author":"Maalouf","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10384-013-0294-0","article-title":"Beh\u00e7et\u2019s disease ocular attack score 24: Evaluation of ocular disease activity before and after initiation of infliximab","volume":"58","author":"Kaburaki","year":"2014","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_70","unstructured":"(2022, October 18). Classification Criteria for Beh\u00e7et Disease Uveitis\u2014ScienceDirect. Available online: https:\/\/www-sciencedirect-com.proxy.insermbiblio.inist.fr\/science\/article\/pii\/S0002939421001835?via%3Dihub."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ajo.2021.07.036","article-title":"Comment on \u201cClassification Criteria for Beh\u00e7et Disease Uveitis\u201d","volume":"235","author":"Onal","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40942-021-00318-4","article-title":"Fluorescein angiographic findings and Behcet\u2019s disease ocular attack score 24 (BOS24) as prognostic factors for visual outcome in patients with ocular Behcet\u2019s disease","volume":"7","author":"Keorochana","year":"2021","journal-title":"Int. J. Retina Vitr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/25785826.2020.1800244","article-title":"Evaluation of disease activity in uveoretinitis associated with Beh\u00e7et\u2019s disease","volume":"44","author":"Keino","year":"2021","journal-title":"Immunol. Med."},{"key":"ref_74","unstructured":"(2022, November 01). Full Article: The Relationship between Fluorescein Angiography Leakage after Infliximab Therapy and Relapse of Ocular Inflammatory Attacks in Ocular Beh\u00e7et\u2019s Disease Patients. Available online: https:\/\/www-tandfonline-com.proxy.insermbiblio.inist.fr\/doi\/full\/10.1080\/09273948.2019.1641611."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: A multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajo.2012.03.035","article-title":"Intravitreal infliximab for sight-threatening relapsing uveitis in Beh\u00e7et disease: A pilot study in 15 patients","volume":"154","author":"Markomichelakis","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/IAE.0000000000001109","article-title":"Intravitreal infliximab in refractory uveitis in Behcet\u2019s disease: A Safety and Efficacy Clinical Study","volume":"36","author":"Hamza","year":"2016","journal-title":"Retina"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/IAE.0000000000003095","article-title":"Monthly intravitreal infliximab in Beh\u00e7et\u2019s disease active posterior uveitis: A Long-Term Safety Study","volume":"41","author":"Refaat","year":"2021","journal-title":"Retina"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2009.12.011","article-title":"Intravitreal adalimumab for refractory uveitis-related macular edema","volume":"117","author":"Androudi","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00417-008-0765-z","article-title":"Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit","volume":"246","author":"Manzano","year":"2008","journal-title":"Graefe Arch. Clin. Exp. Ophthalmol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00417-009-1065-y","article-title":"Evaluation of potential retinal toxicity of adalimumab (Humira)","volume":"247","author":"Tsilimbaris","year":"2009","journal-title":"Graefe Arch. Clin. Exp. Ophthalmol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/IAE.0b013e3181e378af","article-title":"Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema","volume":"31","author":"Bae","year":"2011","journal-title":"Retina"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jconrel.2021.03.035","article-title":"Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models","volume":"333","author":"Rebibo","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e1133","DOI":"10.1212\/NXI.0000000000001133","article-title":"Progranulin Suppressed Autoimmune Uveitis and Autoimmune Neuroinflammation by Inhibiting Th1\/Th17 Cells and Promoting Treg Cells and M2 Macrophages","volume":"9","author":"Wang","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"ref_87","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et\u2019s syndrome","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transplant. Proc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et\u2019s syndrome: A single masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br. J. Ophthalmol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.1780280611","article-title":"Effectiveness of cyclosporin therapy for Beh\u00e7et\u2019s disease","volume":"28","author":"Nussenblatt","year":"1985","journal-title":"Arthritis Rheum."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1034\/j.1600-0420.1998.760118.x","article-title":"Cyclosporin-A therapy in severe uveitis of Beh\u00e7et\u2019s disease","volume":"76","author":"Oge","year":"1998","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S372","DOI":"10.1016\/j.transproceed.2004.01.003","article-title":"Experience with cyclosporine in endogenous uveitis posterior","volume":"36","author":"Hesselink","year":"2004","journal-title":"Transplant. Proc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/14728214.2020.1847271","article-title":"Beh\u00e7et\u2019s disease uveitis: Is there a need for new emerging drugs?","volume":"25","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/1756-185X.12139","article-title":"Methotrexate in ocular manifestations of Behcet\u2019s disease: A longitudinal study up to 15 years","volume":"16","author":"Davatchi","year":"2013","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(94)92549-6","article-title":"Interferon-alpha 2b for refractory ocular Beh\u00e7et\u2019s disease","volume":"343","author":"Feron","year":"1994","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","article-title":"Treatment of ocular symptoms of Beh\u00e7et\u2019s disease with interferon alpha 2a: A pilot study","volume":"82","author":"Eckstein","year":"1998","journal-title":"Br. J. Ophthalmol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-0420.1997.tb00638.x","article-title":"Interferon alpha for ocular Beh\u00e7et\u2019s disease","volume":"75","author":"Accorinti","year":"1997","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: A retrospective monocentric study of 45 patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/kem199","article-title":"Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet\u2019s disease","volume":"46","author":"Berger","year":"2007","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Beh\u00e7et disease: Review of the literature","volume":"33","author":"Zierhut","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis","volume":"244","author":"Urgancioglu","year":"2006","journal-title":"Graefe Arch. Clin. Exp. Ophthalmol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","article-title":"Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Beh\u00e7et\u2019s disease","volume":"8","author":"Wechsler","year":"2000","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et disease: A randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term Efficacy and Safety of Low-Dose and Dose-Escalating Interferon Alfa-2a Therapy in Refractory Beh\u00e7et Uveitis","volume":"129","author":"Onal","year":"2011","journal-title":"Arch. Ophthalmol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","article-title":"Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Beh\u00e7et disease","volume":"146","author":"Gueudry","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","article-title":"Long-term Efficacy of Interferon in Severe Uveitis Associated with Beh\u00e7et Disease","volume":"25","author":"Diwo","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_106","unstructured":"(2022, November 01). Human Recombinant Interferon Alfa-2a for the Treatment of Beh\u00e7et\u2019s Disease with Sight Threatening Posterior or Panuveitis\u2014PubMed, Available online: https:\/\/pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr\/12642304\/."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/annrheumdis-2014-205571","article-title":"Pegylated interferon-\u03b1-2b reduces corticosteroid requirement in patients with Beh\u00e7et\u2019s disease with upregulation of circulating regulatory T cells and reduction of Th17","volume":"74","author":"Lightman","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/09273948.2017.1332768","article-title":"Long-Term Efficacy of Pegylated Interferon Alpha-2b in Beh\u00e7et\u2019s Uveitis: A Small Case Series","volume":"27","author":"Celiker","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_109","first-page":"599","article-title":"Potential of Pegylated Interferon Alpha-2a in Beh\u00e7et Uveitis: A Report of Five Cases","volume":"24","author":"Bielefeld","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"102481","DOI":"10.1016\/j.jaut.2020.102481","article-title":"Comparison of conventional immunosuppressive drugs versus anti-TNF-\u03b1 agents in non-infectious non-anterior uveitis","volume":"113","author":"Leclercq","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et\u2019s disease: Analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et\u2019s disease: A comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","article-title":"Adalimumab therapy for refractory uveitis: A pilot study","volume":"24","author":"Salom","year":"2008","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/jop.2008.0073","article-title":"Adalimumab therapy for refractory uveitis: A pilot study","volume":"24","author":"Serrano","year":"2008","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_115","first-page":"565","article-title":"Adalimumab: A new modality for Beh\u00e7et\u2019s disease?","volume":"66","author":"Missotten","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/09273948.2010.483314","article-title":"Clinical experience with adalimumab in the treatment of ocular Beh\u00e7et disease","volume":"18","author":"Bawazeer","year":"2010","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/09273948.2020.1791346","article-title":"Anti-TNF-\u03b1 Therapy for Refractory Uveitis Associated with Beh\u00e7et\u2019s Syndrome and Sarcoidosis: A Single Center Study of 131 Patients","volume":"30","author":"Kunimi","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10787-020-00697-4","article-title":"Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: Focus on Beh\u00e7et\u2019s syndrome","volume":"28","author":"Silvestri","year":"2020","journal-title":"Inflammopharmacology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients with Active Noninfectious Uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3389\/fphar.2020.00941","article-title":"Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets\u2019 Disease-Associated Uveitis: A Systematic Review and Meta-Analysis","volume":"11","author":"Hu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: Multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Beh\u00e7et\u2019s Disease: National Multicenter Study of 177 Cases","volume":"71","author":"Mesquida","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","article-title":"Ten-Year Retention Rate of Infliximab in Patients with Beh\u00e7et\u2019s Disease-Related Uveitis","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"22227","DOI":"10.1038\/s41598-020-78718-z","article-title":"A 10-year follow-up of infliximab monotherapy for refractory uveitis in Beh\u00e7et\u2019s syndrome","volume":"10","author":"Horiguchi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1080\/09273948.2020.1749857","article-title":"Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation","volume":"29","author":"Liberman","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ophtha.2020.04.009","article-title":"Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease","volume":"127","author":"Lee","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000336187","article-title":"Anti-tumor necrosis factor-\u03b1 agents in noninfectious uveitis","volume":"51","author":"Gueudry","year":"2012","journal-title":"Dev. Ophthalmol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09273948.2013.844265","article-title":"Long-term treatment with golimumab for severe uveitis","volume":"22","author":"Miserocchi","year":"2014","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12348-012-0081-y","article-title":"Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis","volume":"2","author":"William","year":"2012","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_132","first-page":"320","article-title":"Golimumab treatment for complicated uveitis","volume":"31","author":"Miserocchi","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_133","first-page":"1892.e3","article-title":"Golimumab for uveitis","volume":"118","author":"Salom","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ddr.21285","article-title":"Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy","volume":"76","author":"Pereira","year":"2015","journal-title":"Drug Dev. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2217\/imt.15.4","article-title":"Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: Cause for concern?","volume":"7","author":"Atzeni","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Plasencia","year":"2011","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients with Noninfectious Uveitis","volume":"183","author":"Sepah","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/09273948.2017.1355471","article-title":"Tocilizumab for the Treatment of Beh\u00e7et Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy","volume":"26","author":"Oray","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et\u2019s disease: Multicentre retrospective study","volume":"57","author":"Atanes","year":"2018","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_142","first-page":"1575","article-title":"IL-6 Blockade for Beh\u00e7et\u2019s Disease: Review on 31 Anti-TNF Naive and 45 Anti-TNF Experienced Patients","volume":"40","author":"Arida","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of Gevokizumab in Patients with Beh\u00e7et\u2019s Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study","volume":"26","author":"Pavesio","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: An open-label pilot study","volume":"71","author":"Dinarello","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet\u2019s disease: A case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et\u2019s disease: A multicenter retrospective study","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00296-017-3775-5","article-title":"Biological therapies for the treatment of Beh\u00e7et\u2019s disease-related uveitis beyond TNF-alpha blockade: A narrative review","volume":"38","author":"Sota","year":"2018","journal-title":"Rheumatol. Int."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: Results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"AIN457A2208 Study Group Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","article-title":"Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Beh\u00e7et\u2019s phenotype: A multicentre study","volume":"79","author":"Fagni","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","article-title":"Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis","volume":"125","author":"Pepple","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Beh\u00e7et\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3899\/jrheum.141344","article-title":"Alemtuzumab as Remission Induction Therapy in Beh\u00e7et Disease: A 20-year Experience","volume":"42","author":"Mohammad","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"rkx004","DOI":"10.1093\/rap\/rkx004","article-title":"Short-term efficacy of abatacept in the treatment of refractory ocular and cutaneous Beh\u00e7et\u2019s disease","volume":"1","author":"Novello","year":"2017","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et\u2019s disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"(2018). Daclizumab withdrawn from the market worldwide. Drug Ther. Bull., 56, 38.","DOI":"10.1136\/dtb.2018.4.0604"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/14656566.2017.1361408","article-title":"Small molecules as therapy for uveitis: A selected perspective of new and developing agents","volume":"18","author":"Pleyer","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_160","unstructured":"(2022, November 01). A Pilot Study of Tofacitinib for Refractory Beh\u00e7et\u2019s Syndrome\u2014PubMed, Available online: https:\/\/pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr\/32461206\/."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","article-title":"Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis","volume":"27","author":"Bauermann","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et\u2019s Syndrome\u2014A Phase 2, Placebo-Controlled Study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of Apremilast for Oral Ulcers in Beh\u00e7et\u2019s Syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"626792","DOI":"10.3389\/fimmu.2020.626792","article-title":"Apremilast in Refractory Beh\u00e7et\u2019s Syndrome: A Multicenter Observational Study","volume":"11","author":"Vieira","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3648\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:41:20Z","timestamp":1760125280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":165,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["jcm12113648"],"URL":"https:\/\/doi.org\/10.3390\/jcm12113648","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]}}}